Abstract Recombinant human erythropoietin (rhEPO) has been extensively used as a pharmaceutical product for treating anemia. Glycosylation of rhEPO affects the biological activity, immunogenicity, pharmacokinetics, and in-vivo clearance rate of rhEPO. Characterization of the glycosylation status of rhEPO is of great importance for quality control. In this study, we established a fast and comprehensive approach for reliable characterization and relative quantitation of rhEPO glycosylation, which combines multiple-enzyme digestion, hydrophilic-interaction chromatography (HILIC) enrichment of glycopeptides, and tandem mass spectrometry (MS) analysis. The N-linked and O-linked intact glycopeptides were analyzed with high-resolution and high-accuracy (HR-AM) mass spectrometry using an Orbitrap. In total, 74 intact glycopeptides from four glycosylation sites at N 24 , N 38 , N 83 , and O 126 were identified, with the simultaneous determination of peptide sequences and glycoform compositions. The extracted ion chromatograms based on the HR-AM data enabled relative quantification of glycoforms. Our results could be extended to quality control of rhEPO or could help establish detection approaches for glycosylation of other proteins.
Introduction
The glycoprotein human erythropoietin (EPO) is a hormone mainly synthesized by the kidneys and liver [1] . It regulates erythrocyte (red blood cell) production through controlling the proliferation, differentiation, and survival of the erythroid progenitors [2] , and has an important function in other biological processes [3, 4] , including wound healing and response to neuronal injury. Because of its important biological functions, recombinant human erythropoietin (rhEPO) was the first hematopoietic growth factor to be cloned [5] . It has been extensively used as a pharmaceutical product for the treatment of anemia caused by cancer chemotherapy and by chronic kidney disease and many other diseases [6] since it first became available as a drug in 1988 [7] . It is also wellknown for its misuse in endurance sports, and has been forbidden by the World Anti-Doping Agency since 1989 [8] . A variety of types of rhEPO are currently commercially available from different manufacturers.
EPO has three N-linked glycosites at Asn-24, Asn-38, and Asn-83, and a single O-linked glycosylation site at Ser-126. Previous studies have revealed that glycosylation determines the pharmacological properties of rhEPO [9] . The glycoform distributions on each site cause great heterogeneities on the mature protein, whereas the absence of glycosylation greatly reduces the stability of the intermediate species and changes the folding kinetics of erythropoietin [10] . The N-glycan moieties, in particular the sialic-acid residues that are usually attached at the non-reducing end of the glycans, have a significant effect on the in-vivo bioactivity of rhEPO [11, 12] .
There are differences in the microheterogeneity of glycosylation between exogenous and endogenous EPO [13] . rhEPO therapeutics produced in nonhuman mammalian cell lines are often modified with the nonhuman sialic acid Nglycolylneuraminic acid (Neu5Gc) instead of Nacetylneuraminic acid (Neu5Ac) [14] , a feature which has usually been ignored in drug development. However, recent research has indicated that humans can produce Neu5Gc-specific antibodies which can promote drug clearance [15] . Given its significant effect on the function of the protein, a comprehensive analysis of the glycosylation status of EPO is important to the development of biopharmaceuticals from the perspective of efficacy, safety, and the manufacturing process [16] .
Intact rhEPO glycoprotein isoforms have mainly been separated and analyzed by isoelectric focusing (IEF) [14] , capillary electrophoresis (CZE) [17] , sodium dodecylsulfate polyacrylamide-gel electrophoresis (SDS-PAGE) [18] , and capillary isoelectric focusing (CIEF) [19] at the protein level, without revealing detailed information regarding the glycoforms and the existence of specific glycans, for example Neu5Gc. In several recent reports, detection of the glycosylation sites and of the glycan structures have been accomplished separately, with the glycans being released from the protein by either chemical or enzymatic cleavage, followed by mapping of the glycosylation sites by protease digestion. The released glycans were analyzed by MS after treatment, either by an array of different exo-glycosidases or by fluorescent labelling [20] . These methods could not supply information on site-specific glycoforms. Recently, site-specific glycan information for rhEPO was obtained by a multidimensional strategy comprising a shallow anion exchange gradient in the first dimension, followed by hydrophilic-interaction chromatography (HILIC) in the second dimension [21] . Unfortunately, the complexity of the processes and the time required limit the applicability of the method. Therefore, a highly effective method for rapid and extensive characterization of site-specific glycosylation of rhEPO is necessary for verification of the quality of different preparations of biopharmaceutical products.
Intact glycopeptide analysis is an ideal strategy, which could provide information on glycosites and glycan isoforms at the same time. Liquid chromatography-electrospray-ionization mass spectrometry (LC-ESI-MS) has recently become a powerful technique for the analysis of intact glycopeptides, and can simultaneously identify the peptide sequence and the site-specific glycan structures [22, 23] . However, analysis of intact glycopeptides is still a challenging task because glycosylation sites are usually resistant to protease digestion, and produce missed cleavages which could result in large glycopeptides [24] that fall outside the practical working mass range for tandem MS. Optimized digestion conditions should therefore be considered, for example the use of a different enzyme or the combined use of more than one enzyme [23] . Furthermore, heterogeneity and limited ionization of glycopeptides in peptide mixtures usually result in low response during mass-spectrometry detection [25] .
In this study, we developed a systematic strategy based on high resolution-accurate mass spectrometry (HR-AM), including multiple-enzyme digestion, HILIC enrichment, and MS-MS analysis, for detailed elucidation of site-specific N-and O-glycosylation status of rhEPO. The combined use of GluC and trypsin digestion effectively generates rhEPO glycopeptides suitable for MS detection, and HILIC capillary has been proved to be useful for glycopeptide separation [26] . In this study, homemade HILIC SPE micro-tips were used to effectively remove non-glycosylated peptides, which may suppress ionization of glycopeptides in MS analysis [27] . MS information, including accurate precursor mass and the characteristic fragmentation patterns of intact glycopeptides, improved confidence in the detection of the glycosylation sites and their microheterogeneities. Next, relative quantification of the site-specific glycoforms was achieved on the basis of the extracted ion chromatograms (XIC) of identified glycopeptides. Overall, our results reveal that the presented approach is simple and powerful for simultaneous characterization and relative quantification of site-specific N-and O-glycosylation in rhEPO, and may be extended to analysis of other glycoproteins.
Materials and methods
Chemicals rhEPO produced in a Chinese hamster ovary cell line was obtained from Harbin Pharmaceutical Group (Harbin, CHN). Trypsin (sequencing-grade modified) and endoproteinase Glu-C (Glu-C) were supplied by Promega (Madison, WI, USA). PNGase F was obtained from New England Biolabs (Beverly, MA). Formic acid (FA), ammonium hydrogen carbonate (NH 4 HCO 3 ), and HPLC-grade acetonitrile (ACN) were purchased from Sigma-Aldrich (Sigma, USA). Dithiothreitol (DTT) and iodoacetamide (IAA) were obtained from ACROS (Belgium). A Milli-Q water-purification system used to obtain deionized water and 3 kDa Microcon centrifugal filter devices were purchased from Millipore (Bedford, MA, USA). ZIC-HILIC material was bought from Sequant (Umea, Sweden), the 3 M Empore C8 disk was bought from 3 M Bioanalytical Technologies (Minnesota, USA), and 10 μL extended-length pipet tips were obtained from Axygen (California, USA). All chemicals used in the preparation of buffers and solutions were of analytical-reagent grade or better. For enrichment of the intact glycopeptides, homemade HILIC SPE micro-tips were used. A small piece of C8 membrane was taken from a 3 M Empore C8 disk and pushed into the end of a 10 μL extended-length pipet tip using a blunt needle, and then 500 μg ZIC-HILIC material was packed as described elsewhere [28] . The HILIC SPE micro-tip was washed three times with 50 μL 80 % ACN-1 % FA. For sample application to the HILIC SPE micro-tip, 40 μL 80 % ACN-1 % FA was added to 10 μL of a tryptic rhEPO digest, and the mixture was loaded on to the micro-tip three times to enable binding of glycopeptides. The micro-tip was washed with 80 % ACN-1 % FA to remove the non-glycopeptides, and the glycopeptides were eluted with 5 % ACN-1 % FA. Then, the flow-through was dried and stored at −20°C until further use.
Liquid chromatography and electrospray-ionization mass spectrometry
Peptide mixtures or enriched glycopeptides were analyzed using an online nanoflow-liquid-chromatography and electrospray-ionization-mass-spectrometry system (EASYnLC Q Exactive). The sample was loaded by an auto-sample loading system and then separated by use of a 10 cm long, 75 μm inner-diameter analytical column packed with reversed-phase 3 μm C18 material. Mobile phase A consisted of 0.1 % formic acid and 2 % ACN in water, and mobile phase B consisted of 0.1 % formic acid and 2 % water in ACN; a linear mobile phase B gradient from 5 % to 30 % with a flow of 450 nL min −1 was applied for 40 min. The Q-Exactive ion source was operated at 2.0 kV. For full MS survey scans the AGC target was 3×e 6 , and the scan range was m/z 400 to 2000 with a resolution of 70,000. The 20 most intense peaks with charge state ≥2 were selected for sequencing and fragmented in the HCD cell with a normalized collision energy of 25 %. For data-dependent MS-MS scans the AGC target was 1×e 5 , and the maximum injection time was 120 ms with a resolution of 17,500. The exclude-isotope option was on, and the dynamic exclusion time was set at 9 s.
Raw files from the Q-Exactive were searched by Proteome Discovery version 1.3 using the SEQUEST search engine with the Percolator function. The mass tolerance was set at 20 ppm for precursor ions, and 20 mmu for product ions. Oxidation (Met), carbamidomethyl (N-terminus), and deamidated (Asn) were chosen as dynamic modifications; carbamidomethyl (Cys) was chosen as a fixed modification. A user-defined enzyme was used, with a rule that proteins should be digested after amino acid K (Lys)/R (Arg)/E (Glu) sites, excluding KP (Pro)/RP, and that three missed cleavages were allowed. A false discovery rate (FDR) of 1 % was estimated, and applied at the peptide level. Table 1 Glycopeptides of rhEPO generated by three digestion strategies (Trypsin (K/R), GluC (D/E), GluC (E)+trypsin (K/R)) 
Results and discussion
Optimization of the analytical strategy
The objective of this study was to provide a method for analysis of intact glycopeptides. However, glycosylation frequently places the tryptic N-glycopeptides beyond the range of transmission through the mass spectrometer because of the added mass from glycans; in addition, the glycans tend to shield the proximal protease-cleavage sites. Specifically, for the EPO analysis there is no cleavage site between N 24 and N 3 8 , a n d t h e r e s u l t i n g p e p t i d e E A E N I T T G C AEHCSLNENITVPDTK is too large for MS analysis if bearing glycans, as shown in Table 1 . Endoproteinase Glu-C can separate the two glycosylation sites effectively [29] ; however, Glu-C digestion results in a large peptide for site N 83 . rhEPO was therefore processed with serial digestion by Glu-C and trypsin in NH 4 HCO 3 , because the combined proteases cleave the protein at E/K/R. In this way, rhEPO glycopeptides with suitable molecular weights and charge states are generated for mass-spectrometry detection. MS analysis. For a thorough investigation of all glycopeptide structures by mass spectrometry, enrichment or purification steps are often crucial to remove non-glycosylated peptides and improve the ionization and detection efficiency.
Hydrophilic-interaction chromatography (HILIC) provides retention of highly polar hydrophilic compounds that might be difficult to retain on reversed-phase (RP) material, and is thus very suitable for the separation and enrichment of glycopeptides [30] . As can be clearly seen from Fig. 1 , the number of spectra from glycopeptides obtained after HILIC enrichment was approximately 1.5 to 3 times that obtained from the digest mixture without enrichment: before HILIC enrichment we could only detect 569 spectra containing Y 1 (peptide + HexNAc) product ions from N 24 , 360 spectra from N 38 , and 104 spectra from N 83 , which improved to 901, 1399, and 185, respectively, after HILIC enrichment. 
Sorting and assignment of glycopeptide spectra in tandem MS
The rhEPO digestion mixture or HILIC-enriched glycopeptide fraction was separated by reversed-phase liquid chromatography and then analyzed by mass spectrometry. The variables for high-energy collisional dissociation (HCD) to identify intact glycopeptides had been optimized in our previous study [31] . Because of the relatively low abundance of glycopeptides, we adjusted the tandem-MS method by setting longer injection times and an increased resolution to improve the quality of glycopeptide spectra. Glycopeptide precursor ions generated a series of specific products, resulting in the observation of mono-, di-, or trisaccharide oxonium ions in glycopeptide spectra, as shown in Fig. 2 The ions from glycan fragmentation were specific diagnostic ions for sorting the tandem mass spectra of glycopeptides. With the HR-AM performance of the Orbitrap, highly specific extraction of spectra from glycopeptides could be achieved. The glycan-fragmentation diagnostic ions described above were used to extract glycopeptide spectra from raw data with an error tolerance of 20 ppm. The logarithmic intensities of these diagnostic ions in the glycopeptide spectra are shown in 
Glycosylation-site characterization
The mixture of rhEPO peptides was deglycosylated by PNGase F and then analyzed by mass spectrometry, with the purpose of increasing the coverage of the protein sequence and assignment of the N-glycosylation sites. Figure 4 shows that approximately 91.57 % sequence coverage of rhEPO was obtained in the study. For the N-linked glycopeptides, the asparagine residues were converted to aspartic-acid residues during deglycosylation by PNGase F. The MS-MS spectrum of one of the deglycosylated peptides is annotated in Fig. 5 . Although the O-linked glycans cannot be removed by PNGase F, the tandem mass spectra of glycopeptides provide some limited peptide-fragmentation information. The spectrum shown in Fig. 6a illustrates that the O-linked glycopeptide contains the amino-acid sequence AISP from its Nterminus, and thus the whole O-linked peptide sequence (AISPPDAAS 126 AAPLR) can be deduced; the MS-MS spectrum of the non-glycosylated counterpart peptide is shown in Fig. 6b .
Site-specific characterization of N-and O-glycopeptides As mentioned above, HCD fragmentation performed with an appropriate energy often generates abundant specific ions, including glycan oxonium ion peaks and Y 1 (peptide + GlcNAc) or Y 0 (peptide) ions from a glycopeptide precursor ion. The presence of B-type and Y-type ions derived from the glycan fragmentations can assist in determination of the glycan moieties of the glycopeptides. In addition, with the sequence or mass of the peptide known from the above experiments, the composition of a glycan attached to the peptide can be calculated by GlycoMod [32] . A list of glycopeptide precursor ions was input as monoisotopic mass, with a mass tolerance of 20 ppm. In total, 74 site-specific glycopeptide isomers were obtained from the tandem mass spectra. Among these there were 31, 28, and 13 glycopeptides from three Nglycosylation sites, N 24 , N 38 , and N 83 , respectively, and two glycopeptides containing O 126 . The molecular-weight distributions of the glycans from those four glycosylation sites are given in Fig. 7a . The HR-AM performance of the mass spectrometer means the identifications of the glycopeptides have high confidence, because more than 95 % of them had mass errors ≤5 ppm (Fig. 7b) . A clear difference between the glycoforms on different glycosites can be seen from the histogram (Fig. 7a) . The mass of glycans from the N 24 and N 38 sites ranges from 1500 to 4900 Da, whereas those from N 83 occur within a narrower range, from 2300 to 4100 Da. Fig. 8 The MS spectrum number of glycopeptides without sialic acid or with Neu5Ac or Neu5Gc, in raw data which contains 9079 glycopeptide spectra in total Site-specific relative abundance of glycopeptide isomers A well-established method for quantification of the different glycoforms in rhEPO samples is isoelectric-focusing gel electrophoresis [14] , which separates the intact glycoprotein isomers and enables the intensities of individual glycoprotein spots to be compared across different samples. However, this method has low sensitivity because of the presence of a large number of glycoforms. Thus, with their increased sensitivity and mass accuracy, mass-spectrometry methods have become increasingly popular for relative quantitative analysis of glycan isomers from rhEPO [33] . In this study, the extracted ion chromatograms (XIC) of identified peptides, extracted by LFQuant [34] , were used to quantify different glycopeptides. The mass-to-charge ratio (m/z) and retention time (RT) of the glycopeptide precursor ions identified above were used to extract the XIC and calculate the peak areas of individual glycopeptides, which were then normalized and are shown in Table 2 . Although accurate absolute quantitation is not possible in the absence of glycopeptide standards, the relative abundances of different glycoforms could be obtained and this information is useful, especially for pharmaceutical quality control.
Moreover, as discussed above, Neu5Gc is known to differ significantly between the rhEPO expressed in nonhuman mammalian cell lines and the endogenous erythropoietin in human serum. Unlike other mammals, humans cannot biosynthesize Neu5Gc [15] . Therefore, Neu5Gc is recognized as a foreign substance by the immune system and antiNeu5Gc antibodies may be produced after injection of a Neu5Gc-containing glycoprotein, which can promote drug clearance. Because Neu5Gc is not expressed in humans, but the rhEPO analyzed here was expressed by CHO cells containing both Neu5Ac and minor amounts of Neu5Gc forms, detection of the relative percentage of Neu5Gc (m/z 308) versus Neu5Ac (m/z 292) in glycopeptides could be useful to distinguish between endogenous and recombinant EPO. As is clear from the data shown in Fig. 8, 4 .7 % of the glycopeptide spectra indicated the presence of Neu5Gc, and 98.5 % of the glycopeptide spectra provided evidence of Neu5Ac. Further inspection of the spectra revealed that most glycopeptides which have Neu5Gc simultaneously have Neu5Ac. Therefore, the content of Neu5Gc glycoforms could be referenced for rhEPO quality control.
Concluding remarks
The approach described here, involving HILIC SPE enrichment, LC-MS detection, and glycopeptide grouping and quantification, has been successfully used for analysis of intact glycopeptides from rhEPO. The coupling of trypsin and GluC digestion enabled a higher sequence coverage and detection of four glycosylation sites. With high resolution and high mass accuracy, specific ions from the tandem spectra were used as diagnostic ions for the identification and grouping of glycopeptide spectra. Glycosylation-site assignments were mainly achieved by accurate mass detection of Y 1 or Y 0 ions, whereas the detailed peptide sequences were determined from MS analysis of deglycosylated peptides. In addition, the MS-MS data provided detailed compositions of the oligosaccharide chains, and the extracted ion chromatograms (XICs) from MS data provided glycopeptide relative-abundance values. Furthermore, the percentage of Neu5Gc was acquired in a straightforward way, building upon our sorting strategy for glycopeptide spectra. Overall, our strategy enables rapid and sensitive, site-specific glycoform characterization and quantification of N-and O-glycopeptides, which are highly suitable for the differential analysis of rhEPO products from different manufacturers, diverse production cell lines, or different batches.
